On a quest to bring its multiple myeloma antibody-drug conjugate Blenrep back to the U.S. | Members of the FDA's Oncologic ...

GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed results were presented Monday at the American Society of Hematology ...

GSK plc’s GSK Specialty Medicines segment includes medicines that prevent and treat diseases like HIV, cancer, asthma and immune-inflammation diseases like lupus. Specialty Medicines now represents ...

GSK (NYSE:GSK) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its antibody-drug conjugate Blenrep as a late-line option and as part ...

The recent FDA approval for GSK's Nucala in COPD treatment and the positive recommendation for Blenrep could significantly enhance the company's revenue and earnings forecasts by expanding its ...

GSK's blood cancer drug Blenrep failed the main goal of a late-stage study designed to show it was better than an existing treatment on the market, the company said on Monday.

The remainder of GSK’s portfolio posted strong results, leading to overall sales growth of 13%. While we expect some moderation in sales growth, the firm’s long-acting HIV drugs (up 52%) and ...

GSK reported 4% year-on-year earnings growth (at constant currency) and core operating profit margin of 33.7%, or 30 basis points better than the same period last year. This was driven by strong ...

GSK itself has suggested it can drive £20bn of additional revenues, Concluding Thoughts - A Solid Quarter Of Growth & A Solidifying Outlook - May Even Offer Some Share Price Upside ...

For the period 2021-2026, GSK now expects sales to grow more than 7% on a CAGR (Compound Annual Growth Rate) basis and adjusted operating profit to increase more than 11%, on the same basis.

FDA Approves GSK’s BLENREP (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.